Intradermal Acupuncture as an Adjunct to SSRI Tapering in Major Depressive Disorder

September 17, 2026 updated by: Mingqi Tu, First People's Hospital of Hangzhou

Clinical Efficacy and Effects on Autonomic Function of Intradermal Acupuncture as an Adjunct to SSRI Tapering in Major Depressive Disorder: A Randomized Controlled Trial

This randomized controlled trial aims to evaluate the clinical efficacy of intradermal acupuncture as an adjunctive intervention to assist selective serotonin reuptake inhibitor (SSRI) dose reduction or discontinuation in adult patients with major depressive disorder (MDD). Participants receiving SSRIs and planning gradual dose reduction or discontinuation will be randomly assigned to one of three groups: SSRI tapering alone, sham intradermal acupuncture plus SSRI tapering, or intradermal acupuncture plus SSRI tapering. Clinical outcomes and autonomic nervous system function will be assessed to determine the effectiveness and potential mechanisms of intradermal acupuncture in facilitating SSRI reduction and alleviating withdrawal-related symptoms.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

114

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 18-60 years, irrespective of sex;
  • A DSM-5 diagnosis of major depressive disorder, currently in full or partial remission, clinically stable for the preceding 3 months, and not meeting the criteria for a current major depressive episode;
  • Continuous antidepressant treatment for at least 6 months, currently receiving a single SSRI, with the SSRI type and dose unchanged for at least 4 weeks before enrollment;
  • Willing to taper the SSRI and deemed clinically suitable for gradual dose reduction by a psychiatrist;
  • Provision of written informed consent.

Exclusion Criteria:

  • Severe uncontrolled primary medical conditions
  • Depression secondary to substances, medical illness, other psychiatric disorders (e.g., bipolar disorder, schizophrenia), or major bereavement
  • Active suicidal ideation
  • Pregnancy or lactation
  • Cognitive impairment
  • Bleeding disorders or allergy to adhesive materials
  • Participation in another clinical trial within the past month

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: SSRI Tapering Group

Participants receive standard SSRI dose reduction or discontinuation under psychiatric supervision for 8 weeks.

Participants will receive only standard oral SSRI antidepressant dose reduction, with dosage adjustments determined by a specialist physician, for a duration of 8 weeks.

Sham Comparator: SSRI Tapering + Sham Intradermal Acupuncture

Participants receive standard SSRI tapering combined with sham intradermal acupuncture for 8 weeks.

Participants will receive only standard oral SSRI antidepressant dose reduction, with dosage adjustments determined by a specialist physician, for a duration of 8 weeks.

The sham intradermal needles are identical to the intradermal acupuncture needles in size, color, and material, with the needle body replaced by a thin silicone pad. The sham needles are applied to the selected acupoints and retained for 72 hours, followed by a 1-day rest period after removal. Acupoints: Shenmen (HT 7), Neiguan (PC 6), Sanyinjiao (SP 6), and Taichong (LR 3).

Experimental: SSRI Tapering + Intradermal Acupuncture

Participants receive standard SSRI tapering combined with intradermal acupuncture for 8 weeks.

Participants will receive only standard oral SSRI antidepressant dose reduction, with dosage adjustments determined by a specialist physician, for a duration of 8 weeks.

According to the location of the acupoints, intradermal acupuncture needles (φ0.20 × 1.5 mm or φ0.20 × 1.2 mm) are inserted vertically into the skin while avoiding blood vessels and retained for 72 hours, followed by a 1-day rest period after removal. During the retention period, participants are instructed to press the needles 3-4 times daily, with each stimulation lasting approximately 1 minute and an interval of 4 hours between sessions; the stimulation intensity is limited to the maximum level tolerated by the participant. Acupoints: Shenmen (HT 7), Neiguan (PC 6), Sanyinjiao (SP 6), and Taichong (LR 3).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SSRI Dose Reduction Rate
Time Frame: Week 4, Week 8 (end of treatment), Week 12 (follow-up)

Percentage reduction in SSRI dosage from baseline to each assessment point, calculated as:

(Baseline dose - Post-treatment dose) / Baseline dose × 100%

Week 4, Week 8 (end of treatment), Week 12 (follow-up)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in SSRI Dosage
Time Frame: Week 4, Week 8, Week 12

Absolute change in SSRI dose from baseline.

Week 4, Week 8, Week 12
Depression Severity (HAMD-17)
Time Frame: Baseline, Week 4, Week 8, Week 12

Clinician-rated Hamilton Depression Rating Scale (17-item).

Baseline, Week 4, Week 8, Week 12
Depression Severity (SDS)
Time Frame: Baseline, Week 4, Week 8, Week 12

Self-Rating Depression Scale.

Baseline, Week 4, Week 8, Week 12
The Asberg Rating Scale for Side Effects (SERS)
Time Frame: Baseline, Week 4, Week 8, Week 12

The Asberg Rating Scale for Side Effects

Baseline, Week 4, Week 8, Week 12
Discontinuation-Emergent Signs and Symptoms (DESS)
Time Frame: Scheduled assessments at Weeks 0, 4, 8, and 12, with additional symptom-triggered assessments as clinically indicated.
Scheduled assessments at Weeks 0, 4, 8, and 12, with additional symptom-triggered assessments as clinically indicated.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Autonomic Nervous System Function (HRV Parameters)
Time Frame: Baseline, Week 8

Time-domain and frequency-domain HRV parameters measured using 24-hour Holter monitoring.

Baseline, Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

October 31, 2028

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

January 29, 2026

First Submitted That Met QC Criteria

January 29, 2026

First Posted (Actual)

February 5, 2026

Study Record Updates

Last Update Posted (Actual)

September 22, 2026

Last Update Submitted That Met QC Criteria

September 17, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2025KY394-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.